Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827177 | 0.84 | KMT2A (0.52) | GAAKMT2AMEN1MAPK1MAPT | |
| SCHEMBL6718886 | 0.83 | BRD4 (0.62) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8348797 | 0.81 | SLC1A3 (0.48) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28609335 | 0.80 | RAB9A (0.55) | GAAMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6718687 | 0.80 | RAB9A (0.55) | GAAMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6718773 | 0.80 | RAB9A (0.55) | GAAMAPTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6718171 | 0.79 | KLK7 (0.63) | GAAKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6717139 | 0.78 | GAA (0.46) | GAAKMT2AMEN1MAPK1MAPT | |
| SCHEMBL3704664 | 0.78 | GAA (0.61) | GAAKMT2AMEN1MAPK1MAPT | |
| SCHEMBL8348878 | 0.77 | CTSS (0.54) | GAAKMT2AMEN1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | GAA 136/4885KMT2A 2020/4885MEN1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.